M0
Showing 1 - 25 of >10,000
Stratification for pT4bN0M0 Colorectal Cancer Following
Completed
- Colorectal Cancer
- multivisceral resection
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Oct 30, 2023
Lung Adenocarcinoma, Lymph Node Metastasis Trial in Shanghai (Selective Lymph Node Dissection)
Recruiting
- Lung Adenocarcinoma
- Lymph Node Metastasis
- Selective Lymph Node Dissection
-
Shanghai, Please Select, ChinaChaoqiang Deng
Sep 4, 2023
Oral Squamous Cell Carcinoma, Neck Dissection Trial (Elective neck dissection, Therapeutic neck dissection)
Not yet recruiting
- Oral Squamous Cell Carcinoma
- Neck Dissection
- Elective neck dissection
- Therapeutic neck dissection
- (no location specified)
Apr 10, 2023
Early Supraglottic Squamous Cell Carcinoma With Advance
Recruiting
- Supraglottic Squamous Cell Carcinoma
- Early Stage (T1-T2, N0-N1,M0)
- TORS
-
Yvoir, Namur, BelgiumCHU UCL Namur
Nov 3, 2022
Esophageal Cancer Trial in Moscow (Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.,
Recruiting
- Esophageal Cancer
- Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
- Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
-
Moscow, Russian FederationN.N. Blokhin National Medical Research Center of Oncology
Oct 2, 2022
Oral Cancer, PD-1 Trial in Guangzhou (PD-1 with chemo, upright surgery)
Recruiting
- Oral Cancer
- PD-1
- PD-1 with chemotherapy
- upright surgery
-
Guangzhou, Guangdong, ChinaSun yat-sen memorial hospital
Nov 12, 2023
Esophageal Squamous Cell Carcinoma Trial in Tokyo (Chemoradiotherapy)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Chemoradiotherapy
-
Tokyo, JapanNational Cancer Center Hospital
Apr 5, 2022
Colorectal Cancer, Adjuvant Chemo Trial in Guangzhou (wait and watch, adjuvant chemo)
Recruiting
- Colorectal Cancer
- Adjuvant Chemotherapy
- wait and watch
- adjuvant chemotherapy
-
Guangzhou, Guangdong, ChinaSixth Affiliated Hospital of Sun Yat-sen University
Jan 25, 2022
Urinary Bladder Cancer Trial in Guangzhou (Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin)
Recruiting
- Urinary Bladder Cancer
- Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin
-
Guangzhou, Guangdong, ChinaZhujiang Hospital
Jan 6, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Induction chemo plus Concurrent chemo, Concurrent chemo, IMRT)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Induction chemotherapy plus Concurrent chemotherapy
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 17, 2022
Rectal Cancer Trial in Sabadell (drug, radiation, procedure)
Completed
- Rectal Cancer
- Capecitabine (Xeloda)
- +3 more
-
Sabadell, Barcelona, SpainCorporació Parc Taulí
Nov 15, 2021
Rheumatoid Arthritis Trial in Montpellier (Abatacept (M3-M12), TNF Inhibitor (M3-M12), TNF Inhibitor (M0-M3))
Not yet recruiting
- Rheumatoid Arthritis
- Abatacept (M3-M12)
- +2 more
-
Montpellier, FranceCentre Hospitalier Universitaire de Montpellier
Jun 16, 2022
Urinary Bladder Tumors Trial in Xi'an (drug, procedure, radiation)
Not yet recruiting
- Urinary Bladder Neoplasms
- Tislelizumab Injection
- +2 more
-
Xi'an, Shaanxi, ChinaFirst Affiliated Hospital of Xian Jiaotong University
Dec 26, 2022
Rectal Cancer, Adenocarcinoma Trial in Seongnam (Tailored surgery, Total mesorectal excision (TME))
Recruiting
- Rectal Cancer, Adenocarcinoma
- Tailored surgery
- Total mesorectal excision (TME)
-
Seongnam, Korea, Republic ofSeoul National University Bundang Hospital
Jan 5, 2022
Rectal Adenocarcinoma Trial in Baltimore (FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}, Low dose fractionated
Terminated
- Rectal Adenocarcinoma
- FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}
- Low dose fractionated radiation therapy (LDFRT)
-
Baltimore, MarylandUmmc Msgcc
Oct 6, 2021
NSCLC Trial in Shanghai (VATS, Thoracotomy)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- VATS
- Thoracotomy
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 20, 2022
Mouth Tumors, Carcinoma, Squamous Cell Trial in Shanghai (drug, procedure, radiation)
Recruiting
- Mouth Neoplasms
- Carcinoma, Squamous Cell
- TPF induction chemotherapy
- +2 more
-
Shanghai, Shanghai, ChinaNinth People's Hospital, School of Medicine, Shanghai Jiao Tong
Oct 5, 2022
Urothelial Carcinoma Bladder, PD-1 Inhibitor Trial in Shanghai (Tislelizumab, Gemcitabine, Cisplatin)
Recruiting
- Urothelial Carcinoma Bladder
- PD-1 Inhibitor
- Tislelizumab
- +2 more
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 15, 2022
End-stage Kidney Disease Trial in Brampton, Toronto (SUPPORT-DIALYSIS with Access to Output Report and Information Hub,
Not yet recruiting
- End-stage Kidney Disease
- SUPPORT-DIALYSIS with Access to Output Report and Information Hub
- SUPPORT-DIALYSIS Only
-
Brampton, Ontario, Canada
- +1 more
Aug 22, 2022
Gastric Cancer, Adjuvant Chemo, XO Trial in Seoul (Docetaxel and capecitabine and oxaliplatin, capecitabine and oxaliplatin)
Recruiting
- Gastric Cancer, Adjuvant Chemotherapy, XO
- Docetaxel and capecitabine and oxaliplatin
- capecitabine and oxaliplatin
-
Seoul, Korea, Republic ofAsan Medical Center
Dec 30, 2022
Anterior Cruciate Ligament Reconstruction Trial in Storrs (Active Comparator: 0.25 m/s asymmetric session first, Active
Recruiting
- Anterior Cruciate Ligament Reconstruction
- Active Comparator: 0.25 m/s asymmetric session first
- Active Comparator: 0.50 m/s asymmetric session first
-
Storrs, ConnecticutUniversity of Connecticut
Jul 27, 2023
NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
- Befotertinib + Icotinib placebo
- Icotinib + Befotertinib placebo
-
Beijing, China
- +2 more
Sep 20, 2023
Esophageal Squamous Cell Carcinoma Trial in Fuzhou (adjuvant treatment)
Recruiting
- Esophageal Squamous Cell Carcinoma
- adjuvant treatment
-
Fuzhou, Fujian, ChinaFujian Medical University Union Hospital
Nov 10, 2021